Alligator Bioscience promotion Laura von Schantz to CTO

13 February 2023

Swedish immuno-oncology company Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the promotion of Laura von Schantz to the post of chief technology officer (CTO), and her joining the executive management team.

In this role, Dr von Schantz Laura will oversee all technical aspects in the development of Alligator's best-in-class preclinical and clinical pipeline, including lead assets mitazalimab, a CD40 agonist currently in Phase II clinical development, and ATOR-1017, a Phase II-ready 4-1BB agonist.

Prior to that, Dr von Schantz was director, antibody engineering where she was responsible for Alligator's technology platform.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK